taxonomy (3)
protein (5)
source (3)
structure (1)
composition (1)
disease (2)
reference (5)
site (20)
peptide (31)
- Homo sapiens (Human)
- Rattus norvegicus (Norway rat)
- Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
Taxonomy
- Prostaglandin-h2 d-isomerase / Homo sapiens P41222
- Recombinant mature angiotensin-converting enzyme 2 - DRAFT DATA / Homo sapiens Q9BYF1
- Uromodulin / Homo sapiens P07911
- Uncharacterized protein from Erythrocyte Membrane / Rattus norvegicus
- Recombinant Spike glycoprotein (HEK293) - DRAFT DATA / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) P0DTC2
Protein
- Urine (UBERON_0001088)
- HEK293 (CVCL_0045)
- Erythrocyte (CL_0000232) Plasma Membrane (GO_0005886)
Source
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
Reported structure
- Hex:7 HexNAc:5 (avg mass : 2168.9871 )
Composition
- Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2. (2020 - Asif Shajahan, Stephanie Archer-Hartmann, Nitin T. Supekar, Anne S. Gleinich, Christian Heiss, and Parastoo Azadi) / Status : Unreviewed
- Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2 (2020 - Asif Shajahan, Nitin T. Supekar, Anne S. Gleinich, Parastoo Azadi) / Status : Unreviewed
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- The asparagine-linked sugar chains of the glycoproteins in rat erythrocyte plasma membrane--fractionation of oligosaccharides liberated by hydrazinolysis and structural studies of the neutral oligosaccharides. (1982 - Matsumoto A, Yoshima H, Maeda S, Shiraishi N, Kobata A) / Status : Reviewed
Reference
- Prostaglandin-h2 d-isomerase / Homo sapiens
- Recombinant mature angiotensin-converting enzyme 2 - DRAFT DATA / Homo sapiens
- Uromodulin / Homo sapiens
-
Uncharacterized protein from Erythrocyte Membrane / Rattus norvegicus
- Undefined site
- Recombinant Spike glycoprotein (HEK293) - DRAFT DATA / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
Reported glycosite
- MFVFLVLLPLVSSQCVNLTTR (21aa)
- FVFLVLLPLVSSQCVN (16aa)
- SVVAPATDGGLNLTSTFLR (19aa)
- TQSLLIVNNATNVVIK (16aa)
- GWIFGTTLDSKTQSLLIVNNATNVVIK (27aa)
- NNKSWMESEFRVYSSANNCTFE (22aa)
- NNKSWMESEFRVYSSANNCTFE (22aa)
- NNKSWMESEFR (11aa)
- VYSSANNCTFEYVSQPFLMD (20aa)
- LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHR (35aa)
- PQGFSALEPLVDLPIGINITR (21aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSEK (18aa)
- YNEN (4aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- SVGLPNMTQGFWENSML (17aa)
- PNMTQG (6aa)
- FPNITNLCPFGEVFN (15aa)
- FALLMTNCYATPSSNATDPLK (21aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- DPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (57aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- ENSVAYSNNSIAIPTNFTISVTTEILPVSMTK (32aa)
- TPPIKDFGGFNFSQILPDPS (20aa)
- IKDFGGFNFSQILPDPSK (18aa)
- AHFPREGVFVSNGTHWFVTQR (21aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDK (63aa)
- AHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCD (41aa)
- NHTSPDVDLGDISGINAS (18aa)
- NLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIV (37aa)
- LNEVAKNLNE (10aa)
Mass spectrometry observed peptide
-
- N-Linked / Complex (avg mass : 2168.9871)
-
Uncharacterized protein from Erythrocyte Membrane / Rattus norvegicus
- Undefined site
-
- Hex:7 HexNAc:5 / N-Linked (avg mass : 2168.9871)
- Urine (UBERON_0001088)
- HEK293 (CVCL_0045)
- N-Linked / Complex / Gal(b1-4)GlcNAc(b1-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-3)[Gal(b1-3)Gal(b1-4)GlcNAc(b1-2)Man(a1-6)]Man(b1-4)GlcNAc(b1-4)GlcNAc
- Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins using High-Resolution Mass Spectrometry (2020 - Yong Zhang, Wanjun Zhao, Yonghong Mao, Shisheng Wang, Yi Zhong, Tao Su, Meng Gong, Xiaofeng Lu, Jingqiu Cheng, Hao Yang) / Status : Unreviewed
- Deducing the N- and O- glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2 (2020 - Asif Shajahan, Nitin T. Supekar, Anne S. Gleinich, Parastoo Azadi) / Status : Unreviewed
- Comprehensive characterization of N- and O- glycosylation of SARS-CoV-2 human receptor angiotensin converting enzyme 2. (2020 - Asif Shajahan, Stephanie Archer-Hartmann, Nitin T. Supekar, Anne S. Gleinich, Christian Heiss, and Parastoo Azadi) / Status : Unreviewed
- Distinct urinary glycoprotein signatures in prostate cancer patients (2018 - Rebeca Kawahara, Fabio Ortega, Livia Rosa-Fernandes, Vanessa Guimarães, Daniel Quina, Willian Nahas, Veit Schwämmle, Miguel Srougi, Katia R.M. Leite, Morten Thaysen-Andersen, Martin R. Larsen and Giuseppe Palmisano) / Status : Unreviewed
- Prostaglandin-h2 d-isomerase / Homo sapiens
- Recombinant mature angiotensin-converting enzyme 2 - DRAFT DATA / Homo sapiens
- Uromodulin / Homo sapiens
- Recombinant Spike glycoprotein (HEK293) - DRAFT DATA / Severe acute respiratory syndrome coronavirus 2 (2019-nCoV)
- MFVFLVLLPLVSSQCVNLTTR (21aa)
- FVFLVLLPLVSSQCVN (16aa)
- SVVAPATDGGLNLTSTFLR (19aa)
- TQSLLIVNNATNVVIK (16aa)
- GWIFGTTLDSKTQSLLIVNNATNVVIK (27aa)
- NNKSWMESEFRVYSSANNCTFE (22aa)
- NNKSWMESEFRVYSSANNCTFE (22aa)
- NNKSWMESEFR (11aa)
- VYSSANNCTFEYVSQPFLMD (20aa)
- LVRDLPQGFSALEPLVDLPIGINITRFQTLLALHR (35aa)
- PQGFSALEPLVDLPIGINITR (21aa)
- NGTITDAVDCALDPLSE (17aa)
- NGTITDAVDCALDPLSEK (18aa)
- YNEN (4aa)
- YNENGTITDAVDCALDPLSETK (22aa)
- SVGLPNMTQGFWENSML (17aa)
- PNMTQG (6aa)
- FPNITNLCPFGEVFN (15aa)
- FALLMTNCYATPSSNATDPLK (21aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- ILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (51aa)
- DPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWR (57aa)
- AGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPR (36aa)
- ENSVAYSNNSIAIPTNFTISVTTEILPVSMTK (32aa)
- TPPIKDFGGFNFSQILPDPS (20aa)
- IKDFGGFNFSQILPDPSK (18aa)
- AHFPREGVFVSNGTHWFVTQR (21aa)
- EGVFVSNGTHWFVTQR (16aa)
- EGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDK (63aa)
- AHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCD (41aa)
- NHTSPDVDLGDISGINAS (18aa)
- NLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIV (37aa)
- LNEVAKNLNE (10aa)
Source
Suggested structure
Reference
Reported glycosite
Mass spectrometry observed peptide
Disease
Reported glycosite
